Skip to main content
. 2018 Jun 11;18:37. doi: 10.1186/s12911-018-0606-x

Fig. 6.

Fig. 6

The simulation of full dose-response curves for the two antibodies, ipilimumab (a) and tremelimumab (b) in the free-diffusion model. The % increase in the CD28/B7 complex during the full-dose response simulations with ipilimumab and tremelimumab are also plotted (c)